Literature DB >> 18180545

Inorganic arsenic in drinking water and bladder cancer: a meta-analysis for dose-response assessment.

Huei-An Chu1, Douglas Crawford-Brown.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18180545      PMCID: PMC3732405          DOI: 10.3390/ijerph200704040010

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


× No keyword cloud information.
In our previous paper, “Inorganic Arsenic in Drinking Water and Bladder Cancer: A Meta-Analysis for Dose-Response Assessment”, 2006, 3(4), 316–322, there were several errors in the table of data used in the analysis. In particular: The paper of Bates et al. [1] incorrectly listed units of concentrations. They reported in units of milligrams rather than micrograms (see the last entries in Table 3 of their paper). In the paper by Chiou et al. [2] we introduced an error ourselves. We listed the arsenic exposure level as ≤ 50; 50–70; 71+. These should be ≤ 50; 50–700; 710+. With these corrections, the pooled estimate of slopes from the seven studies using the fixed effects model becomes was 0.001 (95% CI: 0.001, 0.002), with the unit of lnRR per unit increase of exposure (exposure is in μg/L as in our original paper). The chi-square statistic was quite large (i.e. Q = 497.752 on 6 degrees of freedom, p= 0.00), which rejects the null hypothesis of homogeneity and means there was evidence of heterogeneity. Using the random-effect model, and including only the five studies identified in the original paper as most relevant (excluding Bates et al [1] and Kurttio et al [3]), the pooled estimate of the slopes from the five studies was found to be 0.002 (exposure also in units of per μg/L) (95% CI: −0.001, 0.006). The new result of the meta-analysis still supports the claim that there is a positive dose-response relationship between exposure to arsenic in drinking water and bladder cancer. Table 1 summarizes the revised results of the absolute risk (AR) calculation for bladder cancer associated with a variety of proposed MCLs (maximum contaminant levels) using different estimates from the meta-analysis: the best estimate, the upper-bound and lower-bound estimates of the slope factor. The best (revised) estimate of the slope factor from the meta-analysis is 1.64 × 10−5 (with unit of probability per μg/kg/day), with the upper bound of 5.38 × 10−5. These slope factors from the meta-analysis are lower than the ones from the EPA (1.5 × 10−3) and NRC (8.85 × 10−4).
Table 1:

Risk of bladder cancer at different MCLs

MCL (ppb)AR (u_95)AR (Mean)AR (L_95)
0000
1−1.80E-071.08E-06−1.80E-07
3−5.39E-073.27E-06−5.39E-07
5−8.98E-075.48E-06−8.98E-07
10−1.79E-061.11E-05−1.79E-06
20−3.56E-062.29E-05−3.56E-06
50−8.78E-066.30E-05−8.78E-06
If readers would like the revised figures and tables from the paper, please contact the corresponding author, at the above-referenced address.
  3 in total

1.  Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan.

Authors:  H Y Chiou; S T Chiou; Y H Hsu; Y L Chou; C H Tseng; M L Wei; C J Chen
Journal:  Am J Epidemiol       Date:  2001-03-01       Impact factor: 4.897

2.  Case-control study of bladder cancer and exposure to arsenic in Argentina.

Authors:  Michael N Bates; Omar A Rey; Mary L Biggs; Claudia Hopenhayn; Lee E Moore; David Kalman; Craig Steinmaus; Allan H Smith
Journal:  Am J Epidemiol       Date:  2004-02-15       Impact factor: 4.897

3.  Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland.

Authors:  P Kurttio; E Pukkala; H Kahelin; A Auvinen; J Pekkanen
Journal:  Environ Health Perspect       Date:  1999-09       Impact factor: 9.031

  3 in total
  2 in total

Review 1.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

2.  Acetylated H4K16 by MYST1 protects UROtsa cells from arsenic toxicity and is decreased following chronic arsenic exposure.

Authors:  William Jaime Jo; Xuefeng Ren; Feixia Chu; Maria Aleshin; Henri Wintz; Alma Burlingame; Martyn Thomas Smith; Chris Dillon Vulpe; Luoping Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2009-09-02       Impact factor: 4.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.